Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma - DSMM XI trialIn: British journal of haematology: the official journal of the British Society for Haematology and the European Haematology Association - Oxford [u.a.]: Wiley-Blackwell, Bd. 179.2017, 4, S. 586-597; http://dx.doi.org/10.1111/bjh.14920

Determination of a cutoff time point for prophylactic exchange of central venous catheters for prevention of central venous catheterrelated bloodstream infections in patients with hematological malignanciesIn: Infection control and hospital epidemiology: the official journal of the Society for Healthcare Epidemiology of America - Cambridge: Cambridge Univ. Press, Bd. 38.2017, 7, S. 888-889; http://dx.doi.org/10.1017/ice.2017.92

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia - a study of the East German Haematology and Oncology Study Group (OSHO)In: Journal of cancer research and clinical oncology: official organ of the Deutsche Krebsgesellschaft - Berlin: Springer, Bd. 142.2016, 1, S. 305-315; http://dx.doi.org/10.1007/s00432-015-2045-8